Point-of-Care Opioid Testing Market Aims to Surpass US$ 725.1 Million by 2033

By 2023, it is projected that the point-of-care opioid testing market would be valued US$ 450.9 million. Over the course of the projection period, the market is expected to increase at a 4.9% CAGR, reaching US$ 725.1 million by 2033. Point-of-care opioid testing has grown significantly in the market in recent years due in part to the expanding opioid epidemic, rising public awareness of drug usage, and the need for efficient testing methods. For as long as there is a demand for accurate and timely drug test solutions, the market is expected to continue rising.

The demand for point-of-care opioid testing is expected to continue rising due to the ongoing opioid epidemic and the need for effective monitoring and intervention. Governments, healthcare providers, workplaces, and law enforcement agencies are increasingly recognizing the importance of rapid and accurate drug testing to address the crisis. This demand will be a significant driver for market growth.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-17625

Advancements in testing technologies, including immunoassays, biosensors, molecular diagnostics, and digital health platforms, are enhancing the performance, sensitivity, specificity, and connectivity of point-of-care opioid testing devices. These technological innovations improve the accuracy, speed, and user experience of testing, driving market growth and adoption.

Point-of-care opioid testing is expanding beyond traditional healthcare settings, such as hospitals and clinics, into non-traditional settings like workplaces, home care, and telehealth. The convenience and accessibility of testing in these settings address the need for decentralized healthcare and patient-centric testing, creating new market opportunities.

Key Takeaways:

• The point-of-care opioid testing industry in the United States is predicted to reach US$ 227.4 million by 2033, increasing at a 4.2% CAGR.
• The point-of-care opioid testing industry in the United Kingdom is estimated to reach a market value of US$ 32.0 million, expanding at a CAGR of 4.3% by 2033.
• During the forecast period, the point-of-care opioid testing industry in China is expected to reach a market value of US$ 54.7 million, securing a 6.4% CAGR.
• The point-of-care opioid testing industry in Japan is predicted to reach US$ 39.9 million by 2033, increasing at a 6.2% CAGR.
• During the forecast period, the point-of-care opioid testing industry in South Korea is expected to reach a market value of US$ 45.4 million, securing a 6.0% CAGR.
• With a CAGR of 4.7% from 2023 to 2033, the test strips is expected to dominate the point-of-care opioid testing industry.
• With a CAGR of 5.2% from 2023 to 2033, the Multi-panel drug test kits is expected to dominate the point-of-care opioid testing industry.
• With a CAGR of 4.9% from 2023 to 2033, the Blood sample is expected to dominate the point-of-care opioid testing industry.
• With a CAGR of 5.4% from 2023 to 2033, the forensic laboratories is expected to dominate the point-of-care opioid testing industry.

Key Players:

• Avon Healthcare
• Triveni Traders Diagnostic Private Limited
• AdvaCare Pharma USA
• BTNX Inc.
• Phamatech
• ADC
• Worldwide Medical Corporation
• Accu-Stat Diagnostics, Inc
• ACON Laboratories, Inc.
• Alere
• Innovacon, Inc.
• Amedica Biotech, Inc
• Branan Medical Corporation
• Biosite Inc
• UCP Biosciences, Inc
• TransMed Company
• Vitrosens Biotechnology
• Abbot
• clarity diagnostics
• Alcotec Company Limited

Key Developments:

• In November 2022, Abbott receives three CES 2023 Innovation awards for advancements in health technology.
• In August 2019, Intoximeters and Abbott recently established a partnership to commercialise Abbott’s SoToxaTM Mobile Test System, a portable oral fluid roadside testing device that accurately and quickly identifies recent drug use.

Segmentation Analysis of the Point-of-care opioid testing Market

By Product:

• Strips
• Cassettes
• Drug Test Dip Cards

By Modality:

• Single-panel Drug Test Kits
• Multi-panel Drug Test Kits

By Sample:

• Saliva
• Blood
• Urine
• Others

By End User:

• Hospitals
• Diagnostics Laboratories
• Forensic Laboratories
• Home Care Settings
• Others

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• The Middle East Africa

Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-17625